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INTRODUCTION
Neuroblastoma (NBL) is the most common extracranial
solid tumor in children and accounts for about 8% of all child-
hood cancers. About two thirds of the children with NBL are
metastatic at diagnosis, and often progressed despite treatment.
Worldwide increase of autologous stem cell transplantations
(ASCT) for NBL over the past decade has been made because
there is a linear-log relationship between drug dosage and
tumor response (1). 
Age, stage and the N-myc gene copy number in tumor cells
are generally considered the most important determinants of
prognosis. Unfavorable tumor histology by the Shimada histo-
pathologic grading system and diploid tumor DNA are addi-
tional risk factors that have been incorporated into a schema
for stratifying patients into low, intermediate or high-risk
groups (1).
Current management of NBL uses risk stratification to mini-
mize late sequelae for patients with favorable features and to
increase the survival of poor-prognosis patients by utilizing
more intensive therapies. Whereas patients with localized
stage I and stage II disease with non-amplified N-myc gene
expression have excellent prognosis for long-term survival,
children over one year of age with stage IV or metastatic dis-
ease and those with N-myc amplified tumors have a 5-yr dis-
ease-free survival of less than 20% by conventional multi-
modal therapeutic approaches (2, 3).
Autologous stem cell rescue after myeloablative chemother-
apy or chemoradiotherapy is now offered as consolidation ther-
apy to children with metastatic NBL and those with stage III
NBL with poor-prognostic factors. Over the past fifteen years,
several institutional and cooperative group clinical trials have
explored the role of this therapy in managing high-risk NBL.
Results from these trials show that 30-45% of patients with
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Autologous Stem Cell Transplantation for the Treatment of 
Neuroblastoma in Korea
Autologous stem cell transplantation (ASCT) for the treatment of high-risk neuro-
blastoma (NBL) is an accepted method for restoring bone marrow depression
after high dose chemotherapy. We retrospectively analyzed eighty eight cases
of NBL that underwent ASCT following marrow ablative therapy at 12 transplant
centers of the Korean Society of Pediatric Hematology-Oncology between Jan-
uary 1996 and September 2000. Seventy nine children were of stage IV NBL and
9 were of stage III with N-myc amplification. Various cytoreductive regimens were
used. However, the main regimen was ‘CEM’ consisting of carboplatin, etoposide
and melphalan, and this was used in 66 patients. Total body irradiation was also
added in 36 patients for myeloablation. To reduce tumor cell contamination, stem
cell infusions after CD34
+ cell selection were performed in 16 patients. Post-trans-
plantation therapies included the second transplantation in 18 patients, interleukin-
2 therapy in 45, 13-cis retinoic acid in 40, 131-meta-iodobenzylguanidine in 4, con-
ventional chemotherapy in 11, and local radiotherapy in 8. Twenty two patients
died, sixty six patients are surviving 1 to 46 months after ASCT (median follow-
up duration, 14.5 months). Although the follow-up period was short and the num-
ber of patients small, we believe that ASCT might improve the survival rate in
high-risk NBL. 
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long-term disease-free survival with myeloablative therapy
followed by ASCT (4, 5).
The purpose of this retrospective study from 12 transplant
centers of the Korean Society of Pediatric Hematology-On-
cology, was to identify the dose of stem cell collection, CD34
+
purging effect, conditioning regimen, engraftment compli-
cation, additional post-transplantation therapy and survival.
MATERIALS AND METHODS
Patients
Surveys and medical records were analyzed retrospectively
for eighty nine patients with NBL who underwent ASCT bet-
ween January 1996 and September 2000. One patient was
excluded because of loss during follow up. Twelve institutions
involved the Korean Society of Pediatric Hematology-Oncolo-
gy participated in this study. These cases were assessed in terms
of age at diagnosis, sex, stage, N-myc gene copy number, disease
status at transplantation, mobilization products, conditioning
regimen, purging, engraftment, post-transplantation com-
plications and additional post-transplantation therapy.
Statistical Analysis
Results are presented as mean±SD, and median with
ranges. Cumulative survival was analyzed using Kaplan-Meier
curves and log-rank statistics with SPSS software for Windows.
A p value of less than 0.05 was considered significant.
RESULTS
Pre-transplantation Patient Characteristics
The patients consisted of 45 males and 43 females with a
median age at diagnosis of 3 yr 7 months (3 months-17 yr 2
months). Primary sites were the adrenal glands in 47 patients,
retroperitoneum in 25, thoracic cavity in 14 and orbital cavi-
ty in 2. Pre-transplant disease status was complete response
in 25 patients, partial response in 48 and relapse in 15. Seven-
ty nine children were of stage IV NBL and 9 were of stage
III with N-myc amplification. Common sites of metastases
included the bone, bone marrow, lymph nodes, liver, orbit
lung and soft tissue in the respective order. The majority of
the prior therapy before ASCT was CCG 3891 that consisted
of cisplatin, etoposide, doxorubicin and cyclophosphamide,
and which was used in 59 patients (Table 1).
Stem Cell Collection
In all patients, a double-lumen Hickman catheter was used
for vascular access during the collection. All stem cells except
one were collected by apheresis, bone marrow harvest and
apheresis were combined in one case, and bone marrow har-
vest was used only in one case. CS-3000 cell separator (N=40)
and COBE-Spectra cell separator (N=58) were used for the
apheresis procedure including double harvest. Stem cell col-
lections were performed in all patients with minimal prob-
lems, such as nausea and vomiting (N=12), headache (N=10),
tingling sensation (N=5), clamping abdominal pain (N=2),
and urticaria (N=1). The mean numbers of collected mononu-
clear cells (MNCs), CD34
+ cells, and CFU-GM were 12.1
±9.3×10
8/kg, 9.1±9.8×10
6/kg and 11.8±14.5×
10
5/kg, respectively. To reduce tumor cell contamination, stem
cell infusion after CD34
+ positive cell purging was performed
in 16 patients. The CEPRATE SC Stem Cell Concentration
System (N=9) and the CliniMACS system (N=7) were used
for CD34
+ cell selection. After column separation using mono-
clonal antibody, CD34
+ cells were reduced to 8.6±6.2×
10
6/kg with a 27.7% cell loss.
Conditioning Regimens
The median duration from diagnosis to ASCT was 8.5
months (2 months-4 yr 3 months). Various cytoreductive
regimens were used, but the main regimen was ‘CEM’ con-
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Age at diagnosis, (months)
Median 43
(range) (3-206)
Sex 
Male:Female 45:43
Primary site 
Adrenal gland 47
Retroperitoneum 25
Thoracic cavity 14
Orbital cavity 2
N-myc amplification status 
Single 17
Amplification 26
Not checked 45
Metastatic sites at diagnosis
None 9
Bone 65
Bone marrow 57
Others* 26
Pre-transplantation disease status
Complete response 25
Partial response  48
Relapsed 15
Prior therapy before autologous stem cell transplantation
Cisplatin, Doxorubicin, Etoposide, Cyclophosphamide 59
Cisplatin, Doxorubicin, Etoposide 16
Cisplatin, Doxorubicin, Etoposide, Cyclophosphamide, 
Vincristine, Dacarbazine 9
Cisplatin, Doxorubicin, Etoposide, Ifosphamide 4
Table 1. Pre-transplantation patient characteristics (N=88)
Others*; liver, lymph node, lung, brain, and soft tissue.sisted of carboplatin, etoposide and melphalan, and was used
in 66 patients. TBI was also added in 36 patients for myeloab-
lation (Table 2). The radiation dose ranged from 540 to 1,200
cGy in 3-5 fractions with or without kidney shielding. 
Engraftment and Post-transplantation Complications
A mean 10.2±9.3×10
8/kg MNCs and 7.3±7.8×
10
6/kg CD34
+ cells were reinfused. Nausea and vomiting were
the most common complications followed by reinfusion
(76.6%), abdominal pain, headache, arrhythmia, and fever
also developed in such order, but no adverse effects were found
in 18.3%. Cells were infused in one dose, but in one case they
were infused twice, once on day 0 and day 1 because DMSO
toxicity and fluid overload were expected. G-CSF and/or GM-
CSF were administered to assist hematopoietic reconstitution.
The mean duration required to achieve an absolute neutrophil
counts (ANC) of ≥500/ L, ≥1,000/ L and platelet counts
of ≥50,000/ L were 10, 12 and 30 days, respectively. No
patient had shown signs of graft failure except for one-death
patients before engraftment.
Gastrointestinal tract problems, such as mucositis and diar-
rhea were the most common post-transplantation complica-
tions (88.0%). Fever developed in 77.6%, but the cause was
proven in only 6 patients, who had cellulitis, pneumonia,
catheter infection, and sepsis. In all cases except 9 prophylac-
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Cisplatin, Doxorubicin, Teniposide, Melphalan  7     1
Carboplatin, Etoposide, Melphalan   28 38
Melphalan, Etoposide   0 5
Others*   1 8
Myeloablative chemoradiotherapy  with TBI  without TBI
Table 2. Myeloablative chemoradiotherapy protocol (N=88)
Others*; Carboplatin, Thiotepa, Melphalan, Ifosfamide, Melphalan,
Neoplatin, Vepocid. TBI; Total body irradiation.
Second transplantation 18
13-cis retinoic acid 40
Interleukin-2 45
MIBG* therapy 4
Conventional chemotherapy 11
Local radiotherapy 8
No additional therapy 30
Post-transplantation therapy  Number
Table 3. Additional post-transplantation therapy for neurob-
lastoma in Korea
MIBG*; 131-meta-iodobenzylguanidine.
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Fig. 1.  Kaplan-Meier probability survival curve for high-risk neu-
roblastoma patients after autologous stem cell transplantation
according to total body irradiation in Korea (N=88). The survival
rate of non-treated group (----) was superior to that of the treated
group (─), but it was not statistically significant (p=0.085). Ticks
indicate censored data.
without TBI (N=52)
with TBI (N=36)
p=0.085
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Fig. 2.  Kaplan-Meier probability survival curve for high-risk neuroblastoma patients after autologous stem cell transplantation according
to additional post-transplantation therapy in Korea (N=88). Patients treated (─) with interleukin-2 (A) and 13-cis retinoic acid (B) had sig-
nificantly higher rates of survival than those in the non-treated (----) group (p=0.001 and p=0.005, respectively). Ticks indicate censored
data.
cis-RA (N=40)
No cis-RA (N=48)
p=0.005
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IL-2 (N=45)
No IL-2 (N=43)
p=0.001
A Btic antibiotics were used.
Additional Post-transplantation Therapy
Details concerning additional post-transplantation therapy
are listed in Table 3. Post-transplantation therapies were as
follows; second transplantation in 18 patients, interleukin-2
(IL-2) therapy in 45, 13-cis retinoic acid (cis-RA) in 40, con-
ventional chemotherapy in 11, local radiotherapy in 8 and
131-meta-iodobenzylguanidine (MIBG) therapy in 4.
Survival
Various prognostic factors were evaluated in this study.
Firstly, those with bone involvement group had a poorer prog-
nosis than those with bone marrow involvement, but this
was not statistically significant (p=0.634). The survival rate
differed according to the duration from diagnosis to ASCT.
Early ASCT group with transplantation done within 1 yr
from initial diagnosis had a better prognosis than late ASCT
group after 1 yr, but this was not statistically significant
(p=0.055). The survival rate was affected by the pre-trans-
plantation disease status. The complete remission status was
the most superior prognostic factor (p=0.004). No significant
difference was found between the survivals of the purging and
non-purging groups (p=0.987) and TBI also caused no sig-
nificant difference in terms of survival (p=0.085) (Fig. 1).
IL-2 and cis-RA therapy were more effective factors of sur-
vival than no further additional treatment (p=0.001 and
p=0.005, respectively) (Fig. 2).
Sixty six patients are alive with a median follow-up of 14.5
months (1-46 months) after ASCT. The Kaplan-Meier post-
transplantation survival curve is shown in Fig. 3. Overall and
disease free survival rate at 46 months after ASCT were 71.4%
and 36.8%, retrospectively. Twenty two patients died after a
median of 6.4 months (1-22 months) post-transplant and
18 patients had recurred. Out of the 22 deaths, 15 patients
were due to complications, such as veno-occlusive disease,
hemorrhage, disseminated intravascular coagulopathy, sepsis,
pneumonitis and pulmonary edema. 
DISCUSSION
Cure of high-risk NBL requires the destruction or removal
of 10
11 to 10
12 tumor cells by a combined modality therapy.
For most patients with high-risk NBL, current non-myeloab-
lative therapy is insufficient to eradicate the tumor cells (1, 6).
Autologous stem cell rescue after myeloablative chemother-
apy or chemoradiotherapy is now offered as a standard con-
solidation therapy to such children (7). Peripheral blood stem
cells (PBSC) are being increasingly utilized as a source of stem
cells for ASCT in NBL and a number of other childhood solid
tumors (8).
NBL was newly classified into low, intermediate, and high-
risk groups according to age at diagnosis, stage, histopathol-
ogy, N-myc gene status, and DNA ploidy by the Pediatric
Oncology Group (POG) and the Childrens Cancer Group
(CCG) (1). High-risk group patients are candidates for ASCT
with myeloablative therapy. In this study, we could not adjust
these criteria because of the retrospective nature of our analy-
sis, but the majority of patients were of stage IV NBL and 9
were of stage III NBL with N-myc amplification. Histopatho-
logic grading and DNA ploidy were not considered in select-
ing the high-risk group. 
Successful peripheral blood stem cell harvests can now be
performed in children weighing less than 20 kg (9). PBSC
mobilization was performed with G-CSF alone at 150-300
g/m2/day or in combination with chemotherapy. Cells were
collected using CS-3000 or a Cobe Spectra separator using a
previously inserted central line. Stem cells were estimated by
mononuclear cells, CD34
+ cells, and CFU-GM, and were suf-
ficient for transplantation.
A theoretical advantage of using PBSC is lower tumor cell
contamination of PBSC harvests, but minimal residual NBL
cells can be detected by several methods. Laver et al. (10)
reported tumor cell contamination of autografts utilizing a
sensitive reverse transcriptase-polymerase chain reaction
(RT-PCR) based method that targets a neuroendocrine pro-
tein gene product found on NBL cells, and which can iden-
tify one tumor cell in 10
7 mononuclear cells. Their results
show that, although both PBSC and marrow products had a
high tumor cell contamination rate, purged bone marrow
samples had a higher level of tumor contamination than un-
purged G-CSF-mobilized PBSC (8, 10, 11). In our previous
study, NBL cells were detected in the peripheral blood of
patients at diagnosis and at relapse using fluorescence in situ
hybridization for the N-myc gene and RT-PCR for thyrosine
hydroxylase induced from cells producing catecholamine, irre-
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Fig. 3.  Kaplan-Meier probability survival curve for high-risk neu-
roblastoma patients after autologous stem cell transplantation in
Korea (N=88). Overall survival (─) rate was 71.4% and event
free survival (----) rate was 36.8%. Ticks indicate censored data.
Overall survival (71.4%)
Event free survival (36.8%)spective of identifiable marrow involvement (data not shown).
In particular, we found the mRNA for thyrosine hydroxy-
lase in mobilized cells, and it was not detected in morpho-
logical analysis. In any future prospective study, it should be
emphasized that these methods are used routinely for the
detection of NBL cells in mobilized PBSC.
Since the purging of multiple PBSC harvests is logistical-
ly difficult, most PBSC transplants performed to date have
used non-purging PBSC. A two to three log depletion of
tumor cells from PBSC harvests can be accomplished using
immunomagnetic CD34
+ selection. Autologous transplan-
tation utilizing CD34
+-selected PBSC has been carried out
in advanced NBL and other poor prognosis pediatric solid
tumors (12, 13).
The majority of post-transplantation relapses in NBL occur
in sites of bulk disease or in previously involved sites, sug-
gesting that tumor cell contamination of the autograft is un-
likely to be the major source of relapse (14). However, gene
marker studies by Rill et al. have conclusively shown that
tumor cells contaminating the autograft can contribute to
relapse (15). In this study, sixteen patients were used with
CD34
+-selected PBSC, but no favorable effects on disease
outcome were found. Hematologic recovery was not delayed,
however they did not achieve lower relapse rates than the non-
purging group.
Drugs that are appropriate for high-dose therapy with NBL
should be tolerated at three to ten times the non-myeloabla-
tive dose, and should have steep and linear dose-response
curves over many logs of tumor cell kill. As with conven-
tional chemotherapy the most effective intensive therapy is
likely to result from using a combination of three or more
agents that are individually effective against NBL. In choos-
ing combination agents, non-cross-resistance and non-over-
lapping toxicities are important considerations. The effec-
tiveness of TBI is controversial. Level of destruction to the
microenvironment required for the restoration of hematopoiesis
may be induced by TBI, but engraftment may be delayed
or even fails.
Moreover, if kidney shielding is not appropriate, hemolyt-
ic uremic syndrome is likely to develop. Moreover, hormon-
al imbalance including growth retardation and the possibil-
ity of the development of a secondary malignancy cannot be
excluded. In this study, various kinds of conditioning regimen
were used with or without TBI. Most of them were CEM
protocol containing carboplatin, etoposide, and melphalan,
while no statistically significance was attached to TBI as part
of the conditioning regimen in terms of prognosis.
Hematologic recovery was linked directly to the number
of infused CD34
+ cells and MNCs. We confirmed that the
early neutrophil recovery after myeloablative conditioning
was followed by higher dose of infused hematopoietic stem
cells. Compared to neutrophils, the time variation until nor-
malization of platelet counts was more pronounced. Time to
platelets ≥50,000/ L was 30 days.
Despite the better results attributed to ASCT in the recent-
ly completed CCG-3891 trial, most patients still relapse fol-
lowing myeloablative chemotherapy or chemoradiotherapy
and autologous stem cell transplantation (6). If minimal resid-
ual disease following stem cell transplantation can be eradi-
cated, better cure rates might be expected (16). Two alterna-
tive approaches being studied in poor prognosis NBL include
the use of differentiating agents and targeted immunothera-
py (17-19). Both approaches are attractive in that they offer
minimal cross-resistance or overlapping toxicity with chemo-
therapy.
In vitro treatment of NBL cell lines with the synthetic cis-
RA results in the morphologic differentiation and growth
arrest of tumor cells and the decreased expression of the N-
myc gene. These effects can also be demonstrated for cell lines
from patients whose tumors are resistant to cytotoxic chemo-
therapy. The validity of this approach was confirmed in the
CCG-3891 trial where patients were randomized to receive
cis-RA versus no further therapy after undergoing either auto-
transplant or consolidation chemotherapy. Those patients who
received cis-RA had a three-year event-free survival of 47%
compared to 25% for those that received no further therapy
(p=0.013) (4). Future cooperative group trials will test whether
the addition of cis-RA during induction chemotherapy will
improve survival in poor-prognosis NBL. The administra-
tion of immunomodulators such as GM-CSF or IL-2 in con-
junction with these antibodies may increase their tumorici-
dal efficacy by enhancing anti-GD2 mediated antibody depen-
dent cellular cytotoxicity (20). Tumor-targeted therapy has
also been used as an additional therapeutic approach for NBL,
either with antibodies directed against NBL cells or with
radiolabeled antibodies or radiolabeled molecules such as
MIBG. This latter molecule has been widely used in Europe
for many years and induces responses in about 30% of patients
with refractory disease. In this study, additional post-trans-
plantation therapies were undertaken, mainly IL-2 and cis-
RA therapies (Table 3). IL-2 and cis-RA therapy were more
effective factors of survival than no further additional post-
transplantation treatment (p=0.001 and p=0.005, respec-
tively).
Over the past fifteen years, several institutional and coop-
erative group clinical trials have explored the role of therapy
in managing high-risk NBL. Results from these trials show
that 30-45% of patients with complete or partial remission
after initial chemotherapy achieve long-term disease-free sur-
vival with myeloablative therapy followed by ASCT (5). In
this study, 22 patients died, and 66 patients are surviving 1
to 46 months after ASCT. Overall survival and disease free
survival of these patients is 71.4% and 36.8%, respectively,
which are very good survival results. However, in this study,
multivariate analysis failed to identify any of the following
as statistically significant prognostic factors except post-trans-
plantation IL-2 or cis-RA therapy: remission status at time
of transplant, purging of bone marrow, TBI, myeloablative
246 K.H. Ryu, H.S. Ahn, H.H. Koo, et al.regimen, age, N-myc status and sex.
In this paper, we compare the outcome of a relatively small
number of cases of patients who prevents our drawing defini-
tive conclusions. A well-designed trial that specifically address-
es prospective protocols is warranted. Nonetheless, some gen-
eral conclusions can be drawn from these trials relating to
the indications, optimal timing, toxicity, and effectiveness
of ASCT in treatment of advanced NBL. 
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